concept · intermediate · partly written
Lymphodepletion: clearing space before cells are infused
Lymphodepletion is chemotherapy given days before an engineered cell infusion to reduce the patient own lymphocytes, which in the studies read improved expansion and persistence of the infused cells.
Also called: lymphodepleting chemotherapy, conditioning
Lymphodepletion in brief
Before CAR T cells are infused, the patient gets chemotherapy that lowers their own white cells. It is part of the treatment: the regimen changes how well the infused cells expand and how long they last. 12
Reported, not yet replicated
Evidence it matters more
In a study of 32 adults with lymphoma, adding fludarabine to cyclophosphamide gave more expansion and persistence of CAR T cells and 50% complete remission against 8% with cyclophosphamide alone (abstract only). Another study linked a stronger response to lymphodepletion with longer progression-free survival (abstract only). The textbook reason, freeing cytokines such as IL-7 and IL-15, was not stated in the sources opened and is unverified. 12
Reported, not yet replicated
A possible cost of the regimen more
The JCAR015 ROCKET trial was stopped after cerebral oedema deaths, and an exploratory analysis reported through trade press linked the heavier fludarabine plus cyclophosphamide cohort to more toxicity. See drugs/jcar015 for the sources and their limits. 1
Our inference
Plain answer
Why it matters
Real numbers
Cy/Flu versus Cy
In 32 adults with lymphoma, 50% complete remission with fludarabine plus cyclophosphamide against 8% with cyclophosphamide alone. 1
Reported, not yet replicated
Teach this
In one sentence
Chemotherapy first, so the infused engineered cells have room to multiply. 1
Reported, not yet replicated
The five-minute version
Without it the infused T cells compete with the patient own lymphocytes and may be limited by immune responses to the mouse-derived binder. Adding fludarabine to cyclophosphamide improved expansion and persistence in one study. The regimen is also linked to toxicity. 1
Reported, not yet replicated
What a listener will ask
Is it to prevent rejection?
For CAR T made from the patient own cells, the sources point to expansion, not rejection.
Is it risk free?
No; the chemotherapy has its own toxicity.
Does cell therapy with donor cells need it?
Donor cells also face rejection; see concepts/graft-rejection-and-immunosuppression.
The common wrong idea
The chemotherapy before CAR T is only there to kill cancer.
It is chosen to help the infused cells expand and persist; the regimen changed outcomes in the studies read.
The one citation to hand over: 1
Still open here
- Is the benefit mainly cytokine availability, removal of competing lymphocytes, or reduced immunity to the mouse-derived binder? No opened source separates these.
Not yet written: Equation.
Linked from
- Graft rejection and immunosuppression: why donor cells are attacked and how that is managed
- Axicabtagene ciloleucel (Yescarta)
- JCAR015
- Tisagenlecleucel (Kymriah)
- CAR T cell therapy
- Stem cell therapy
- If CAR T cells are the patient own cells, why are there antibodies to them, and why do those antibodies not wipe them out?
Sources
- Turtle, C. J., et al.. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine (2016). paper; opened 2026-11-17 all records citing this
- Hirayama, A. V., et al.. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood (2019). paper; opened 2026-11-17 all records citing this
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/concepts/lymphodepletion.json